Cargando…

A Novel Ambroxol-Derived Tetrahydroquinazoline with a Potency against SARS-CoV-2 Proteins

We report synthesis of a novel 1,2,3,4-tetrahydroquinazoline derivative, named 2-(6,8-dibromo-3-(4-hydroxycyclohexyl)-1,2,3,4-tetrahydroquinazolin-2-yl)phenol (1), which was obtained from the hydrochloride of 4-((2-amino-3,5-dibromobenzyl)amino)cyclohexan-1-ol (ambroxol hydrochloride) and salicylald...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krysantieva, Alena I., Voronina, Julia K., Safin, Damir A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002583/ https://www.ncbi.nlm.nih.gov/pubmed/36902093 http://dx.doi.org/10.3390/ijms24054660

Ejemplares similares

Copper(II) Chelates of Schiff Bases Enriched with Aliphatic Fragments: Synthesis, Crystal Structure, In Silico Studies of ADMET Properties and a Potency against a Series of SARS-CoV-2 Proteins
por: Panova, Elizaveta V., et al.
Publicado: (2023)

In silico analyses of betulin: DFT studies, corrosion inhibition properties, ADMET prediction, and molecular docking with a series of SARS-CoV-2 and monkeypox proteins
por: Burkhanova, Tatyana M., et al.
Publicado: (2022)

Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2
por: Alkotaji, Myasar
Publicado: (2020)

Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2
por: Wei, Daibao, et al.
Publicado: (2021)

Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells
por: Carpinteiro, Alexander, et al.
Publicado: (2021)

Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations
por: Bradfute, Steven B, et al.
Publicado: (2020)

Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern
por: Schmitz, Katharina S., et al.
Publicado: (2022)

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
por: Xia, Shuai, et al.
Publicado: (2022)

Synthesis of Novel Derivatives of 5,6,7,8-Tetrahydroquinazolines Using α-Aminoamidines and In Silico Screening of Their Biological Activity
por: Snizhko, Arsenii D., et al.
Publicado: (2022)

Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants
por: Bi, Wenwen, et al.
Publicado: (2022)

Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches
por: Raj, Vinit, et al.
Publicado: (2021)

Active Ingredients of Reduning Injection Maintain High Potency against SARS-CoV-2 Variants
por: Xiao, Zhen, et al.
Publicado: (2022)

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants
por: Desautels, Thomas A., et al.
Publicado: (2023)

Impaired potency of neutralizing antibodies against cell–cell fusion mediated by SARS-CoV-2
por: Wang, Qian, et al.
Publicado: (2023)

Altered severity of the current SARS-CoV-2 in the Kurdistan region of Iraq
por: Hussein, Safin, et al.
Publicado: (2020)

A novel coumarin-triazole-thiophene hybrid: synthesis, characterization, ADMET prediction, molecular docking and molecular dynamics studies with a series of SARS-CoV-2 proteins
por: Omar, Rebaz Anwar, et al.
Publicado: (2023)

Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants
por: Ibarrondo, F. Javier, et al.
Publicado: (2021)

The potency and synergy of plant‐made monoclonal antibodies against the BA.5 variant of SARS‐CoV‐2
por: Sun, Haiyan, et al.
Publicado: (2023)

Inhibition Potencies of Phytochemicals Derived from Sesame Against SARS-CoV-2 Main Protease: A Molecular Docking and Simulation Study
por: Kumar, Anuj, et al.
Publicado: (2021)

Two human monoclonal SARS-CoV-2 antibodies that maintain neutralizing potency against the SARS-CoV-2 Omicron BA.1 and BA.2 variants
por: Zheng, Qianqian, et al.
Publicado: (2022)

Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II α over β
por: Ortega, Jose Antonio, et al.
Publicado: (2020)

Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination
por: Mantus, Grace, et al.
Publicado: (2022)

A high-affinity RBD-targeting nanobody improves fusion partner’s potency against SARS-CoV-2
por: Yao, Hebang, et al.
Publicado: (2021)

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants
por: Makdasi, Efi, et al.
Publicado: (2021)

Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir
por: Shinada, Kanako, et al.
Publicado: (2022)

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
por: Peng, Lei, et al.
Publicado: (2021)

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
por: Peng, Lei, et al.
Publicado: (2022)

Innovative adjuvant augments potency of a SARS-CoV-2 subunit vaccine
por: Peng, Hua, et al.
Publicado: (2022)

Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses
por: Wang, Yingdan, et al.
Publicado: (2022)

Ambroxol for the treatment of fibromyalgia: science or fiction?
por: Kern, Kai-Uwe, et al.
Publicado: (2017)

Value of ambroxol in the treatment of asthmatic bronchitis
por: Du, Xiaoxia, et al.
Publicado: (2020)

Polypharmacology of ambroxol in the treatment of COVID-19
por: Wang, Ziyuan, et al.
Publicado: (2023)

Use of Ambroxol as Therapy for Gaucher Disease
por: Zhan, Xia, et al.
Publicado: (2023)

Inhibitory mechanism of Ambroxol and Bromhexine Hydrochlorides as potent blockers of molecular interaction between SARS-CoV-2 spike protein and human angiotensin-converting Enzyme-2
por: Kehinde, Idowu A., et al.
Publicado: (2022)

Microsecond molecular dynamics simulations revealed the inhibitory potency of amiloride analogs against SARS-CoV-2 E viroporin
por: Jaber, Abdullah All, et al.
Publicado: (2021)

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
por: Zhu, Yuanmei, et al.
Publicado: (2022)

A novel plant‐made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS‐CoV‐2 Omicron variant
por: Jugler, Collin, et al.
Publicado: (2022)

Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations
por: Miersch, Shane, et al.
Publicado: (2021)

Molecular switches regulating the potency and immune evasiveness of SARS-CoV-2 spike protein
por: Wan, Yushun, et al.
Publicado: (2021)

Production of two SARS-CoV-2 neutralizing antibodies with different potencies in Nicotiana benthamiana
por: Frigerio, Rachele, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pchiq429pcdoa57eflu12tt4ha